KR101805400B1 - 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물 - Google Patents

아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물 Download PDF

Info

Publication number
KR101805400B1
KR101805400B1 KR1020170035224A KR20170035224A KR101805400B1 KR 101805400 B1 KR101805400 B1 KR 101805400B1 KR 1020170035224 A KR1020170035224 A KR 1020170035224A KR 20170035224 A KR20170035224 A KR 20170035224A KR 101805400 B1 KR101805400 B1 KR 101805400B1
Authority
KR
South Korea
Prior art keywords
compound
adenosine
formula
tetrahydro
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020170035224A
Other languages
English (en)
Korean (ko)
Inventor
이상구
박종우
김혜옥
이희우
유미라
Original Assignee
퓨쳐메디신 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 퓨쳐메디신 주식회사 filed Critical 퓨쳐메디신 주식회사
Priority to KR1020170035224A priority Critical patent/KR101805400B1/ko
Application granted granted Critical
Publication of KR101805400B1 publication Critical patent/KR101805400B1/ko
Priority to CA3159836A priority patent/CA3159836C/en
Priority to EP18771758.2A priority patent/EP3603647B1/en
Priority to AU2018238996A priority patent/AU2018238996B2/en
Priority to PCT/KR2018/003274 priority patent/WO2018174549A1/ko
Priority to CN201880015381.7A priority patent/CN110381955A/zh
Priority to JP2019547971A priority patent/JP6821050B2/ja
Priority to US16/492,938 priority patent/US11185556B2/en
Priority to CA3057277A priority patent/CA3057277C/en
Priority to US17/458,231 priority patent/US12083140B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • Y10S514/913—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020170035224A 2017-03-21 2017-03-21 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물 Active KR101805400B1 (ko)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020170035224A KR101805400B1 (ko) 2017-03-21 2017-03-21 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물
CA3057277A CA3057277C (en) 2017-03-21 2018-03-21 Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative
AU2018238996A AU2018238996B2 (en) 2017-03-21 2018-03-21 Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative
EP18771758.2A EP3603647B1 (en) 2017-03-21 2018-03-21 Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative
CA3159836A CA3159836C (en) 2017-03-21 2018-03-21 Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative
PCT/KR2018/003274 WO2018174549A1 (ko) 2017-03-21 2018-03-21 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물
CN201880015381.7A CN110381955A (zh) 2017-03-21 2018-03-21 用于预防及治疗青光眼的含有腺苷衍生物的药物组合物
JP2019547971A JP6821050B2 (ja) 2017-03-21 2018-03-21 アデノシン誘導体を含む緑内障の予防及び治療用薬学的組成物
US16/492,938 US11185556B2 (en) 2017-03-21 2018-03-21 Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative
US17/458,231 US12083140B2 (en) 2017-03-21 2021-08-26 Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170035224A KR101805400B1 (ko) 2017-03-21 2017-03-21 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
KR101805400B1 true KR101805400B1 (ko) 2017-12-07

Family

ID=60920336

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020170035224A Active KR101805400B1 (ko) 2017-03-21 2017-03-21 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물

Country Status (8)

Country Link
US (2) US11185556B2 (https=)
EP (1) EP3603647B1 (https=)
JP (1) JP6821050B2 (https=)
KR (1) KR101805400B1 (https=)
CN (1) CN110381955A (https=)
AU (1) AU2018238996B2 (https=)
CA (2) CA3057277C (https=)
WO (1) WO2018174549A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018174549A1 (ko) * 2017-03-21 2018-09-27 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물
US12076334B2 (en) 2017-11-29 2024-09-03 Future Medicine Co., Ltd. Pharmaceutical composition comprising adenosine derivative for prevention and treatment of retinal disease or optic nerve disease

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116350649A (zh) * 2021-12-28 2023-06-30 未来制药有限公司 预防和/或治疗胆管炎或由其引起的肝疾病的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137577A1 (en) * 2007-03-07 2010-06-03 Lak Shin Jeong Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient
WO2012125400A1 (en) * 2011-03-14 2012-09-20 Acorn Biomedical, Inc. Compositions and methods using adenosine a3 receptor antagonists for the treatment of inflammatory eye diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009003750A (es) 2006-10-06 2009-06-18 Univ Pennsylvania Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular.
KR101805400B1 (ko) * 2017-03-21 2017-12-07 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물
KR101820909B1 (ko) * 2017-07-07 2018-01-23 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 만성신장질환 예방 및 치료용 약학적 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137577A1 (en) * 2007-03-07 2010-06-03 Lak Shin Jeong Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient
WO2012125400A1 (en) * 2011-03-14 2012-09-20 Acorn Biomedical, Inc. Compositions and methods using adenosine a3 receptor antagonists for the treatment of inflammatory eye diseases

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018174549A1 (ko) * 2017-03-21 2018-09-27 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물
US11185556B2 (en) 2017-03-21 2021-11-30 Future Medicine Co., Ltd. Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative
US12083140B2 (en) 2017-03-21 2024-09-10 Future Medicine Co., Ltd. Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative
US12076334B2 (en) 2017-11-29 2024-09-03 Future Medicine Co., Ltd. Pharmaceutical composition comprising adenosine derivative for prevention and treatment of retinal disease or optic nerve disease

Also Published As

Publication number Publication date
JP2020511437A (ja) 2020-04-16
CA3057277C (en) 2022-07-26
AU2018238996A1 (en) 2019-10-24
EP3603647B1 (en) 2024-08-21
WO2018174549A1 (ko) 2018-09-27
US20200016186A1 (en) 2020-01-16
AU2018238996B2 (en) 2021-01-28
US20210386771A1 (en) 2021-12-16
EP3603647A4 (en) 2021-01-06
JP6821050B2 (ja) 2021-01-27
CA3159836C (en) 2026-02-10
US12083140B2 (en) 2024-09-10
US11185556B2 (en) 2021-11-30
CA3159836A1 (en) 2018-09-27
CA3057277A1 (en) 2018-09-27
CN110381955A (zh) 2019-10-25
EP3603647A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
KR101709307B1 (ko) 아데노신 유도체를 포함하는 비알콜성 지방간염, 간섬유증 및 간경변증 예방 및 치료용 약학적 조성물
CA2680179C (en) Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient
US12083140B2 (en) Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative
US7199127B2 (en) Purine nucleosides
KR101396092B1 (ko) 아데노신 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 약학적 조성물

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20170321

PA0201 Request for examination
PA0302 Request for accelerated examination

Patent event date: 20170329

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

Patent event date: 20170321

Patent event code: PA03021R01I

Comment text: Patent Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170419

Patent event code: PE09021S01D

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20170901

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20171130

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20171201

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20200825

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20210927

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20220406

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20250217

Start annual number: 9

End annual number: 9